Pharmaceutical industry has witnessed partnerships, licensing, investments and M&A deals for various reasons such as exploring new opportunities with artificial intelligence, R&D, drug pricing and personalized medicine. New collaboration and partnerships were welcomed on the pretext of finding new medicines and to narrow down therapeutic focus by excluding outlying assets. An intelligence report titled, “ ... Read more

Pharmaceutical industry has witnessed partnerships, licensing, investments and M&A deals for various reasons such as exploring new opportunities with artificial intelligence, R&D, drug pricing and personalized medicine. New collaboration and partnerships were welcomed on the pretext of finding new medicines and to narrow down therapeutic focus by excluding outlying assets. An intelligence report titled, “ ... Read more